Integrated Quantitative Investments LLC Takes $393,000 Position in Emergent BioSolutions Inc. (NYSE:EBS)

Integrated Quantitative Investments LLC purchased a new position in Emergent BioSolutions Inc. (NYSE:EBS) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 41,075 shares of the biopharmaceutical company’s stock, valued at approximately $393,000. Integrated Quantitative Investments LLC owned approximately 0.08% of Emergent BioSolutions at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. State Street Corp grew its position in shares of Emergent BioSolutions by 864.7% during the 3rd quarter. State Street Corp now owns 1,911,327 shares of the biopharmaceutical company’s stock valued at $15,960,000 after purchasing an additional 1,713,200 shares in the last quarter. Oak Hill Advisors LP purchased a new position in shares of Emergent BioSolutions in the third quarter worth $9,296,000. American Century Companies Inc. lifted its holdings in Emergent BioSolutions by 23.4% in the 4th quarter. American Century Companies Inc. now owns 2,137,712 shares of the biopharmaceutical company’s stock worth $20,437,000 after buying an additional 404,667 shares during the period. Trexquant Investment LP lifted its position in shares of Emergent BioSolutions by 59.3% in the 4th quarter. Trexquant Investment LP now owns 701,517 shares of the biopharmaceutical company’s stock worth $6,707,000 after purchasing an additional 261,099 shares during the period. Finally, Allspring Global Investments Holdings LLC purchased a new stake in Emergent BioSolutions in the fourth quarter worth $1,831,000. 78.40% of the stock is currently owned by institutional investors.

Emergent BioSolutions Trading Down 6.2 %

Shares of EBS opened at $4.53 on Friday. Emergent BioSolutions Inc. has a twelve month low of $1.82 and a twelve month high of $15.10. The company’s fifty day simple moving average is $7.44 and its 200-day simple moving average is $8.54. The company has a market cap of $246.15 million, a P/E ratio of -1.10 and a beta of 1.80. The company has a current ratio of 2.88, a quick ratio of 1.47 and a debt-to-equity ratio of 1.30.

Emergent BioSolutions (NYSE:EBS) last announced its earnings results on Monday, March 3rd. The biopharmaceutical company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.35) by $0.40. The firm had revenue of $194.70 million for the quarter, compared to the consensus estimate of $254.67 million. Emergent BioSolutions had a negative return on equity of 9.91% and a negative net margin of 18.55%. During the same period in the previous year, the business earned ($0.77) EPS. As a group, analysts expect that Emergent BioSolutions Inc. will post -0.63 EPS for the current year.

Emergent BioSolutions announced that its Board of Directors has initiated a share repurchase program on Monday, March 31st that authorizes the company to repurchase $50.00 million in shares. This repurchase authorization authorizes the biopharmaceutical company to repurchase up to 19% of its shares through open market purchases. Shares repurchase programs are generally a sign that the company’s leadership believes its shares are undervalued.

Insider Buying and Selling

In related news, Director Neal Franklin Fowler sold 35,000 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $5.83, for a total transaction of $204,050.00. Following the completion of the transaction, the director now owns 101,100 shares in the company, valued at $589,413. This represents a 25.72 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 1.20% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the company. HC Wainwright restated a “buy” rating and set a $15.00 price target on shares of Emergent BioSolutions in a report on Tuesday. StockNews.com downgraded Emergent BioSolutions from a “buy” rating to a “hold” rating in a research note on Wednesday, March 5th.

Emergent BioSolutions Company Profile

Emergent BioSolutions Inc, a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax.